Humira — Net revenues
AbbVie Humira — Net revenues decreased by 44.8% to $688M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 38.6%, from $1.12B to $688M. Over 4 years (FY 2021 to FY 2025), Humira — Net revenues shows a downward trend with a -31.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
A decrease in revenue typically signals increased competition from biosimilars or a decline in market share, while stability or growth indicates strong brand loyalty or successful lifecycle management.
Detailed definition
This metric represents the total gross sales of the specific pharmaceutical product line after accounting for returns, a...
Peer comparison
Comparable to revenue metrics for mature, off-patent, or highly competitive pharmaceutical products at peer companies, often analyzed alongside biosimilar market penetration rates.
abbv_segment_humira_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.07B | $5.43B | $5.33B | $4.74B | $5.36B | $5.56B | $5.58B | $3.54B | $4.01B | $3.55B | $3.3B | $2.27B | $2.81B | $2.23B | $1.68B | $1.12B | $1.18B | $993M | $1.25B | $688M |
| QoQ Change | — | +7.0% | -1.7% | -11.2% | +13.2% | +3.7% | +0.4% | -36.5% | +13.3% | -11.6% | -6.9% | -31.3% | +24.0% | -20.9% | -24.5% | -33.4% | +5.3% | -15.8% | +25.5% | -44.8% |
| YoY Change | — | — | — | — | +5.8% | +2.5% | +4.6% | -25.2% | -25.2% | -36.2% | -40.8% | -35.9% | -29.9% | -37.2% | -49.1% | -50.6% | -58.1% | -55.4% | -25.9% | -38.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's humira — net revenues?
- AbbVie (ABBV) reported humira — net revenues of $688M in Q1 2026.
- How has AbbVie's humira — net revenues changed year-over-year?
- AbbVie's humira — net revenues decreased by 38.6% year-over-year, from $1.12B to $688M.
- What is the long-term trend for AbbVie's humira — net revenues?
- Over 4 years (2021 to 2025), AbbVie's humira — net revenues has grown at a -31.6% compound annual growth rate (CAGR), from $20.69B to $4.54B.
- What does humira — net revenues mean?
- The total revenue generated from sales of the Humira product line after accounting for discounts and returns.